Toripalimab is a domestically produced anti-tumor monoclonal antibody targeting PD-1, used for immunotherapy of various cancers.
It belongs to immune checkpoint inhibitors, which attack tumor cells by blocking the binding of PD-1 to its ligand and reactivating T cells.
Drug Archive
Antibody type: Fully humanized IgG4 kappa anti-PD-1 monoclonal antibody
Mechanism of action: Specifically binding to the FG loop of PD-1, blocking its binding to PD-L1/PD-L2, and inducing in vivo phagocytosis and degradation of PD-1 receptors, thereby relieving immune suppression.
Approved indications
According to the latest information, Terizumab has been approved for a total of 13 indications in mainland China, of which 12 have been included in the national medical insurance catalog.
Melanoma: The first approved indication (2018) for unresectable or metastatic melanoma that has failed previous treatment; Starting from 2026, first-line treatment for unresectable or metastatic melanoma will be added.
Nasopharyngeal carcinoma: monotherapy for second-line and above treatment; Combination chemotherapy is used for first-line treatment and is also the first nasopharyngeal carcinoma treatment drug approved by the US FDA.
Urothelial carcinoma: used for locally advanced or metastatic urothelial carcinoma that has failed platinum based chemotherapy; In May 2026, a combination therapy with vediximab will be added for patients with HER2 expression.
Esophageal squamous cell carcinoma: first-line combination chemotherapy for advanced or metastatic esophageal squamous cell carcinoma.
Non small cell lung cancer: first-line combination chemotherapy for driver gene negative non-small cell lung cancer; The indications for perioperative treatment have been extended to stage II-III resectable patients.
Other cancers: extensive small cell lung cancer, renal cell cancer, triple negative breast cancer, hepatocellular carcinoma, etc. have also been approved.
Medication Reminder
It must be evaluated by a doctor before use: it needs to be judged comprehensively based on pathological type, genetic testing (such as PD-L1 expression, MSI status), and physical condition, and may not be applicable to all patients.
Immune related adverse reactions: can affect organs such as the skin, thyroid, lungs, liver, intestines, and pituitary gland. Common manifestations include rash, fatigue, abnormal thyroid function, diarrhea, cough, etc. Close monitoring is required during medication.
Administration method: intravenous infusion, usually once every 2 or 3 weeks, with dosage calculated based on body weight or fixed dose.
This medicine is a prescription drug and must be used under the guidance of a specialist oncologist. Self medication is not allowed.
International Listing Status
In October 2023, it was approved by the US FDA for the treatment of nasopharyngeal carcinoma, becoming the first Chinese indigenous innovative biological drug approved by the FDA. At present, it has been approved and listed in more than 50 countries and regions in the world.
